Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2016

View Archived Issues

Neurospecific gene therapy improves cognition in Down syndrome model

Mitsubishi Tanabe Pharma offers overview of fourth quarter of fiscal 2015

HTG Molecular Diagnostics enters research collaboration agreement with BMS

Phenomenome Discoveries validates OvAware blood test for early detection of ovarian cancer

Leica Biosystems to collaborate with UCLA on digital pathology

Researchers present novel biomarker discoveries in pediatric diseases

FDA grants fast track designation to Edge Therapeutics' EG-1962

GlaxoSmithKline patents EZH2 inhibitors

Ziarco reports topline results from phase IIa study of ZPL-389 in atopic dermatitis

AbbVie patents reveal CFTR channel correctors

ApoGlyx describes AQP-9 inhibitors

Bristol-Myers Squibb reports development of BTK inhibitors

Prima BioMed and Sydys enter licensing agreement to advance CVac program

CellCept approved in Japan for lupus nephritis

Baxdela meets the primary endpoints in confirmatory phase III study

Mundipharma and Purdue Pharma take over responsibility for development of E-52862

Janssen Pharmaceutica presents RORgammaT modulators

Serendex and Nobelpharma sign Japanese license agreement for Molgradex

Mylan announces agreement to acquire Renaissance's topicals business

Scynexis' SCY-078 receives FDA orphan drug designation

Pfizer set to acquire Anacor Pharmaceuticals

Novel small molecule shows promise for the treatment of retinal disease

Thermo Fisher Scientific obtains FDA clearance for Elia anti-TG and anti-TPO tests

Antitumor immune responses seen with TNFSF18 fusion protein GITRL-Fc

Crown Bioscience establishes NSCLC PDX models with non-canonical EGFR mutations

WHO issues new recommendations on rapid detection and shorter treatment regimen for MDR-TB

Bayer Yakuhin launches Ventavis inhalation solution

AstraZeneca announces positive phase III results for benralizumab in severe asthma

New pan-RAF and VEGFR-2 dual inhibitor blocks tumor growth in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...